Merck & Co Inc. (MRK) News Headlines

▮ More

Date

Headline

5/6/2021 9:50:15 AM Fusion, Merck To Evaluate Fusion's Targeted Alpha Therapy In Combination With Merck's KEYTRUDA

5/6/2021 9:23:50 AM Fusion Collaborates With Merck To Evaluate Fusion' TAT In Combination With Merck' KEYTRUDA In Patients With Solid Tumors

5/6/2021 6:50:20 AM Merck To Present Data Spanning More Than 20 Cancer Types From Its Oncology Research Program At ASCO

5/3/2021 8:05:53 AM Merck: Spinoff Organon Expected To Drive Sustainable Growth

5/3/2021 6:48:58 AM Merck: Organon's Standalone Co. To Deliver Low To Mid-single Digit Revenue Growth Off 2021 Base

4/29/2021 7:02:11 AM Merck Q1 Adj. Profit Declines

4/29/2021 6:46:31 AM Merck Q1 GAAP EPS $1.25; Non-GAAP EPS $1.40

4/29/2021 6:00:25 AM Merck & Co Q1 21 Earnings Conference Call At 8:00 AM ET

4/27/2021 8:04:51 AM Merck To License COVID-19 Treatment Molnupiravir To Five Indian Generics Makers

4/27/2021 6:49:05 AM Merck Enters Non-exclusive Voluntary Licensing Deals For Molnupiravir With Five Indian Generics Manufacturers

4/26/2021 7:40:14 AM Merck Aims To Achieve Carbon Neutrality Across Operations By 2025

4/26/2021 7:24:19 AM Merck Announces Ambitious Goals To Achieve Carbon Neutrality Across Its Operations By 2025

4/19/2021 8:55:05 AM Covid-19 Antiviral Oral Drug Found Effective In Hamster Study

4/15/2021 8:19:59 AM Merck, Ridgeback Biotherapeutics Update Covid Drug Development Program

4/15/2021 8:17:01 AM Merck To Discontinue Development Of COVID-19 Drug 'MK-7110'

4/15/2021 7:31:07 AM Merck Discontinues Development Of MK-7110 For Treatment Of Hospitalized Patients With COVID-19

4/15/2021 7:06:27 AM Merck, Ridgeback Biotherapeutics Provide Update On Clinical Development Program For Molnupiravir

4/15/2021 3:08:15 AM GlaxoSmithKline Discontinues Feladilimab Cancer Trials

4/14/2021 8:05:49 AM Merck Announces Funding Support Of 20th Community-based Project In Safer Childbirth Cities Initiative

4/8/2021 8:42:15 PM Merck's Organon Announces Pricing Of Senior Notes Offering